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ABSTRACT
Background: Penile cancer is a rare malignancy associated with high rates of mortality and 
morbidity. Currently, the efficacy of adjuvant treatment (AT), including radiotherapy and 
chemotherapy, for penile cancer remains unclear. Therefore, we investigated the prognostic 
factors for treatment outcomes and the efficacy of AT in consecutive patients who underwent 
penectomy for penile cancer at multiple Korean institutions between 1999 and 2013.
Methods: AT was defined as the administration of chemotherapy, radiotherapy, or both 
within 12 months after initial treatment. All patients were divided into two groups according 
to the AT status.
Results: Forty-three patients (median age 67.0 years) with a median follow-up after 
penectomy of 26.4 (interquartile range: 12.0–62.8) months were enrolled. Patients with AT 
had a significantly higher pathologic stage. However, no differences in age, histologic grade, 
or type of surgery were identified according to the presence of AT. The 3- and 5-year cancer-
specific survival (CSS) rates were 79.0% and 33.0%, respectively. In a multivariate analysis, 
American Joint Committee on Cancer (AJCC) stage ≥ III disease was an independent predictor 
of CSS and recurrence-free survival (RFS). However, AT was not associated with CSS and RFS. 
The type of primary surgical treatment and inguinal lymph node dissection at diagnosis were 
also not significantly associated with overall survival, CSS, or RFS.
Conclusion: AJCC stage ≥ III disease, which mainly reflects lymph node positivity, is a 
significant prognosticator in patients with penile cancer. By contrast, AT does not seem to 
affect CSS and RFS.
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INTRODUCTION
Penile squamous cell carcinoma (PSCC) is a rare malignancy with a highly variable 
incidence.1 Annually, PSCC accounts for 0.4%–0.6% of all malignant neoplasms occurring 
in men in the USA,2 although rates as high as 10% have been reported among men in 
developing countries within Asia, Africa, and South America.3 In 2013, the Korea Central 
Cancer Registry recorded that PSCC accounted for 0.1% of all newly diagnosed malignancies 
in men.4 Despite the very low incidence, PSCC has disappointingly high mortality and 
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morbidity rates. Adjuvant treatments (ATs), including chemotherapy (AC) or radiotherapy 
(AR), have been administered to patients with high-grade penile tumors in the same manner 
as for other solid cancers, with the aim of improving the poor prognosis. However, sufficient 
data are not available to support decision-making about the use of AT.
Currently, there is no consensus regarding standardized treatment for PSCC management. 
Given the absence of high-level evidence regarding this rare disease, the National 
Comprehensive Cancer Network (NCCN) relied on the experience of penile cancer experts 
when setting guidelines.5 Although recent studies reported the efficacy of AT for PSCC,6,7 
additional data may help to standardize the management of this malignancy.5 Therefore, 
this study aimed to present a composite of the outcomes of treatment, including AT, among 
patients with PSCC who were treated at multiple Korean institutions.
METHODS
Study population and data collection
We reviewed the medical records of all cases diagnosed with PSCC and treated at three 
hospitals between 1999 and 2013. A total of 43 patients received treatment at Sinchon 
Severance Hospital, Gangnam Severance Hospital, and the National Health Insurance Service 
Ilsan Hospital. Patients' characteristics, including clinico-pathologic data such as the age at 
diagnosis, clinical history and physical examination, disease staging, and primary treatment 
options, and the presence of AT, were reviewed.
PSCC diagnoses were made according to the clinical history, physical examination, and 
biopsy results. Primary treatment for PSCC included partial or radical penectomy with 
concomitant inguinal lymph node dissection (ILD), which included ipsilateral or ilioinguinal 
lymphadenectomy via contralateral superficial inguinal or ilioinguinal dissection according 
to the clinical condition. After treatment of the primary tumor, the decision to proceed to ILD 
was based on the European Association of Urology (EAU) guidelines of 2002, 2004, and 2009.8-10
Clinical staging was performed according to international guidelines and was based on data 
from a physical examination and cross-sectional computed tomography (CT), magnetic 
resonance imaging (MRI), or positron emission tomography (PET)-CT. Tumor staging was 
standardized using the American Joint Committee on Cancer (AJCC) system,11 and tumors 
were graded as well, moderately, or poorly differentiated. All surgical specimens were 
analyzed by uropathologists at each institution.
Postoperative follow-up evaluations were conducted at 3-month intervals during year 1, 
6-month intervals during year 2, and annually thereafter, with laboratory and imaging studies 
as clinically indicated. Death certificates were used to assess causes of death, which were 
corroborated via chart review.
Assessment of adjuvant treatment
AT was defined as the performance of AC, AR, or both within 12 months after penectomy. AC 
comprised cisplatin, methotrexate, and bleomycin (CMB) administered at respective doses 
of 100 mg/m2 over 1 hour, 25 mg/m2, and 10 mg/m2 over 1 hour, respectively. Four AC cycles 
were scheduled at intervals of 21 days. Carboplatin was substituted for cisplatin in patients 
with a serum creatinine clearance rate < 50. Patients treated with at least two cycles of 
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chemotherapy were considered to have received AC. The treatment protocols and follow-up 
schedules were surgeon-dependent. Tumors were not routinely staged postoperatively prior 
to AT.
Statistical analysis
Patients were divided into two groups according to the presence of AT (AC, AR, or both): AT 
(+) (n = 12; 27.9%) and AT (−) (n = 31; 72.1%). Categorical associations were evaluated using 
the Mann-Whitney test. A review of the clinical notes facilitated a calculation of survival rates 
and construction of Kaplan-Meier curves, and significant differences were determined using 
the log-rank test. A multivariable analysis was performed using a Cox proportional hazards 
model that included the AJCC disease stage and tumor grade as covariates. Analyses were 
performed using SPSS 23.0 (SPSS, Inc., Chicago, IL, USA). All P values were two-sided, and a 
P value < 0.05 was considered to indicate statistical significance.
Ethics statement
Gangnam Severance Hospital Institutional Review Board approval (IRB No.: 2017-0754-001) 
was obtained for this retrospective study.
RESULTS
Table 1 presents the basic characteristics of patients diagnosed with PSCC at the participating 
institutions from 1999 to 2013. The median age at diagnosis was 67.0 years (interquartile 
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Table 1. Patient characteristics
Valuables Total AT (−) AT (+) P value
No. of cases 43 31 (72.1) 12 (27.9)
Age, yr 67.0 (53.1–72.0) 67.0 (53.8–73.0) 67.1 (48.5–71.0) 0.659
pT stage 0.011
T1/X 19 (44.2) 18 (58.1) 1 (8.3)
≥ T2 24 (55.8) 13 (41.9) 11 (91.7)
pN stage < 0.001
pN0 30 (69.8) 28 (90.3) 2 (16.7)
pN1/pN2 13 (30.2) 3 (9.7) 10 (83.3)
cM stage 0.021
M1 2 (4.7) 0 (0.0) 2 (16.7)
Grade 0.868
Well-moderate 33 (76.7) 24 (77.4) 9 (75.0)
Poorly 10 (23.3) 7 (22.6) 3 (25.0)
AJCC stage < 0.001
≤ Stage II 30 (69.8) 28 (90.3) 2 (16.7)
≥ Stage III 13 (30.2) 3 (9.7) 10 (83.3)
Surgery 0.199
Partial penectomy 37 (86.0) 28 (90.3) 9 (75.0)
Total penectomy 6 (14.0) 3 (9.7) 3 (25.0)
ILD 0.002
Not performed 16 (37.2) 16 (51.6) 0 (0.0)
Performed 27 (62.8) 15 (48.4) 12 (100.0)
AT NE
Chemotherapy 8 (18.6) - 8 (66.7)
Radiotherapy 1 (2.3) - 1 (8.3)
Chemoradiotherapy 3 (7.0) - 3 (25.0)
Data are expressed as numbers (%) or medians (interquartile ranges).
AJCC = American Joint Committee on Cancer, AT = adjuvant treatment, ILD = inguinal lymph node dissection, NE = not evaluable.
range: 53.1–72.0), and patients were followed up for a median of 26.4 months (12.0–62.8). 
The majority of primary lesions presented on the glans (n = 26; 60.5%) and occasionally 
involved both the glans and adjacent structures (urethra [n = 9; 20.9%], shaft [n = 8; 18.6%]). 
Partial penectomy was performed in the majority of cases (n = 37; 86.0%). Twenty-four 
(55.8%) patients were diagnosed with pT stage ≥ T2 disease. The proportion of histologically 
well to moderately differentiated cases was 76.7%. At diagnosis, 24 (55.8%) patients had 
palpable inguinal lymph nodes. ILD was performed in 27 patients, and positive nodes were 
found in 20 patients. The presence of AT was found to correlate significantly with higher 
pathologic stage (pT, pN, cM, and AJCC stage ≥ III), but did not correlate with age, histologic 
grade, or type of surgery.
The overall survival rate was 69.8% (n = 30), and the penile cancer-related mortality rate was 
14.0% (n = 12); furthermore, one patient died of unknown causes. The 3- and 5-year cancer-
specific survival (CSS) rates were 79.0% and 33.0%, respectively. AJCC stage ≥ III disease and 
AC administration were identified as potential prognostic factors in the univariate analysis. 
However, in a multivariable analysis, only AJCC stage ≥ III was identified as an independent 
predictor of CSS (hazard ratio [HR], 10.59 [1.230–91.219]; P = 0.032) (Table 2). AT and AC 
administration were not significant prognosticators for CSS.
Thirteen (30.3%) patients developed recurrence within a median of 9.5 months (4.6–24.9). 
The administration of AT and AC and an AJCC stage ≥ III were significantly associated with 
RFS in a univariate analysis. Again, only AJCC stage ≥ III remained an independent predictor 
of recurrence-free survival (RFS) in the multivariate analysis (HR, 7.56 [2.254–25.373]; 
P = 0.001) (Table 3). Surgical treatment of the primary lesion (partial penectomy vs. total 
penectomy) and ILD were not significantly associated with CSS or RFS.
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Table 2. Univariate and multivariable analyses of CSS
Valuables Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Age 1.00 (0.927–1.072) 0.931
AJCC stage (≥ stage III) 10.59 (1.230–91.219) 0.032 10.59 (1.230–91.219) 0.032
Type of penectomy (partial) 3.57 (0.652–19.569) 0.142
ILD, yes 2.19 (0.255–18.798) 0.475
Adjuvant treatment, yes 5.06 (0.926–27.674) 0.061
Adjuvant chemotherapy, yes 6.11 (1.116–33.475) 0.037 1.91 (0.253–14.363) 0.532
Grade (well/moderate vs. poor) 0.81 (0.094–6.911) 0.844
CSS = cancer-specific survival, HR = hazard ratio, CI = confidence interval, AJCC = American Joint Committee on Cancer, ILD = inguinal lymph node dissection.
Table 3. Univariate and multivariable analyses of RFS
Valuables Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Age 1.01 (0.953–1.061) 0.843
AJCC stage (≥ stage III) 7.56 (2.254–25.373) 0.001 7.56 (2.254–25.373) 0.001
Type of penectomy (partial) 2.65 (0.714–9.839) 0.145
ILD, yes 1.73 (0.476–6.616) 0.404
Adjuvant treatment, yes 5.53 (1.791–17.069) 0.003 1.57 (0.300–8.218) 0.593
Adjuvant chemotherapy, yes 4.31 (1.438–12.890) 0.009 0.36 (0.038–3.450) 0.378
Grade (well/moderate vs. poor) 0.67 (0.149–3.037) 0.606
RFS = recurrence-free survival, HR = hazard ratio, CI = confidence interval, AJCC = American Joint Committee on Cancer, ILD = inguinal lymph node dissection.
DISCUSSION
To our knowledge, this report describes the first large, multi-institution PSCC case series in 
Korea. As Korea represents a microcosm of the shifting demographics in rapidly developing 
countries, such studies are urgently needed to help characterize the populations at risk for 
PSCC. We found that in contrast to the high PSCC incidence rates in other Asian countries, 
the annual incidence rate in Korea was similar to rates in developed countries.12
The incidence of PSCC tends to increase markedly during the sixth decade of life.13,14 A recent 
study found that the median age of patients with penile cancer in Los Angeles is younger 
than ages reported elsewhere in the US.15,16 However, our observation of a median age of 67.0 
years was similar to that in previous studies. Known risk factors for penile cancer include 
a history of phimosis, poor hygiene, smoking, human papilloma virus (HPV) infection 
(particularly HPV types 16 and 18),17 and especially, a lack of circumcision during childhood, 
which increases the risk by threefold. The situation of circumcision in Korea is unique. 
Notably, this population has undergone the most rapid increase in circumcision since the 
introduction of this procedure in 1945, with a circumcision rate > 100% of male births during 
the period from 1980–2000 was reported.18 Although the circumcision rate of 75.1% in 2012 
was 16.9 percentage points lower than the 92.0% value reported in 2002, it remained much 
higher than rates reported in other countries.19,20 Therefore, this important study not only 
compares the PSCC incidence rates in the Korean population over a 10-year period, but also 
allows a comparison of disease characteristics.
Regarding treatment for PSCC, in recent years, there has been progress in both the methods 
used to treat primary lesions (partial vs. radical penectomy vs. radiotherapy) and perform 
ILD. Most penile cancers are detected as small and distal tumors. Accordingly, the primary 
lesion can usually be managed by glans excision or partial penectomy with reconstruction.21 
Partial penectomy is a feasible primary surgical method with similar oncological outcomes 
(i.e., RFS) as radical penectomy.10 In our study, we observed no significant differences 
in prognosis between patients treated with partial and radical penectomy. Moreover, 
partial penectomy for primary tumors was recommended to minimize the psychological 
and functional effects on patients. Accordingly, a recent report described a high rate of 
conservative primary treatment, with almost 60% of patients undergoing primary penis-
conserving treatment, mainly radiotherapy with or without local excision.22
Previous studies emphasized an association of high-grade disease with an increased 
probability of lymph node metastasis.23-25 However, the significant morbidity associated 
with ILD precludes its use as a prophylactic treatment in patients at low risk of lymph node 
metastases, although the modern modified approaches might reduce the complication 
rates.23,26,27 In our cohort, the performance of ILD did not significantly improve patient 
outcomes. Several risk factors for lymph node metastases have been identified, particularly 
high grade and T2 disease,26,27 and a positive inguinal lymph node is a significant negative 
prognosticator of survival in patients with PSCC.28 Consistent with a previous report, the 
present study identified correlations of an AJCC disease stage ≥ stage III (≥ pT1-3pN1cM0) 
with an unfavorable CSS and RFS.14 Therefore, our study re-confirmed the significant 
association of the lymph node status with survival.
No standardized AT (including AR, AC, or both) has been found to confer a survival benefit 
after penectomy in patients with PSCC. The use of AR may provoke lymphedema in patients 
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who have already undergone extensive groin and pelvic dissection.29 However, AR was 
associated with improved survival and decreased recurrence in a recent multi-institution 
study of 92 patients who received AR for positive pelvic lymph nodes.7 AC has been 
recommended as an additional treatment option for such high-risk cases,8 as it is less likely 
to contribute to lymphedema and increase related morbidity. Although previous studies 
have used CMB and taxol, ifosfamide and cisplatin (TIP), the efficacies of these regimens 
remain controversial in cases involving substantial and significant morbidity and mortality. 
Furthermore, the curative efficacy of AC comprising CMB for advanced penile cancer is low.30 
Similarly, AC with CMB did not improve the outcomes of patients with advanced PSCC in our 
study. The 2017 NCCN guidelines recommend 5-fluorouracil + cisplatin, which has been used 
historically for metastatic penile cancer, as an alternative to TIP.5 However, the efficacy of AC 
after penectomy will remain unclear until the results of randomized trials are obtained.
Urologists select treatment plans for rare diseases such as PSCC after referring to several 
guidelines, such as those published by the NCCN and EAU. However, most published studies 
often describe a low incidence of these diseases in Western countries, and the conclusions 
that can be drawn from the results are limited. Our retrospective analysis included three 
hospitals wherein the treatment outcomes of 43 patients with PSCC who underwent 
penectomy and received AT were evaluated. Therefore, our data are meaningful.
Nonetheless, the present study had several limitations. First, because of the retrospective and 
non-randomized study design, this study could not definitively identify the efficacy of the AT 
for PSCC. The present study reported that AT seems not to be effective in Asians, and a well-
designed study may help to clarify whether AT is effective for Asians. Second, several factors 
affected the heterogeneity in the results, including the small size cohort and the decisions of 
multiple physicians leading to variability in surgical techniques, surveillance methods, and 
pathological interpretations. However, as differences in practice patterns across institutions 
might be reflective of a real-world setting, the conclusions of the present study may be more 
generalizable. Finally, although our study analyzed oncologic outcomes after penectomy and 
AT, we have not provided new solutions.
AJCC stage ≥ III disease, which mainly reflects positive lymph nodes, was significantly 
associated with survival prognoses in patients with penile cancer treated at multiple Korean 
institutions. However, AT did not appear to affect CSS and RFS.
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